PLK1 and breast carcinoma: This could involve techniques such as quantitative PCR, Western blotting, or immunohistochemistry to confirm the overexpression of CHEK1 and PLK1 at both mRNA and protein levels in TNBC tissues compared to normal breast tissues and other breast cancer subtypes.